Aptevo Therapeutics Inc Stock News

First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company advancing differentiated immunotherapies, announced the first presentation of preclinical data for its new trispecific antib...

89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique use of the CRIS-7-derived CD3 binding domain, associated with favorable safety outcomes in the cli...

SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial, industry, scientific and medical conferences this fall, providing the opportunity to highlight continu...

Aptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Aptevo said that Cohort 3 of the trial achieved a 100% remission rate, ...

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA / ACCESS Newswire / September 16, 2025 / Aptevo Therapeutics ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific and ...

New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells Mipletamig-driven clinical validation of the CRIS-7-derived CD3 binding domain underpins Aptevo's introduction of new, trispecific CD3-directed anti-cancer molecules SEATTLE, WASHINGTON ...

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors SEATTLE, WA / ACCESS Newswire / August 13, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company...

Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for...